Wu Zhenjie, Chen Qi, Djaladat Hooman, Minervini Andrea, Uzzo Robert G, Sundaram Chandru P, Rha Koon H, Gonzalgo Mark L, Mehrazin Reza, Mazzone Elio, Marcus Jamil, Danno Alyssa, Porter James, Asghar Aeen, Ghali Fady, Guruli Georgi, Douglawi Antoin, Cacciamani Giovanni, Ghoreifi Alireza, Simone Giuseppe, Margulis Vitaly, Ferro Matteo, Tellini Riccardo, Mari Andrea, Srivastava Abhishek, Steward James, Al-Qathani Ali, Al-Mujalhem Ahmad, Bhattu Amit Satish, Mottrie Alexander, Abdollah Firas, Eun Daniel D, Derweesh Ithaar, Veccia Alessandro, Autorino Riccardo, Wang Linhui
Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Department of Health Statistics, Naval Medical University, Shanghai, China.
Eur Urol Focus. 2022 Jan;8(1):173-181. doi: 10.1016/j.euf.2021.01.014. Epub 2021 Feb 3.
Postoperative renal function impairment represents a main limitation for delivering adjuvant chemotherapy after radical nephroureterectomy (RNU).
To create a model predicting renal function decline after minimally invasive RNU.
DESIGN, SETTING, AND PARTICIPANTS: A total of 490 patients with nonmetastatic UTUC who underwent minimally invasive RNU were identified from a collaborative database including 17 institutions worldwide (February 2006 to March 2020). Renal function insufficiency for cisplatin-based regimen was defined as estimated glomerular filtration rate (eGFR) <50 ml/min/1.73 m at 3 mo after RNU. Patients with baseline eGFR >50 ml/min/1.73 m (n = 361) were geographically divided into a training set (n = 226) and an independent external validation set (n = 135) for further analysis.
Using transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines, a nomogram to predict postoperative eGFR <50 ml/min/1.73 m was built based on the coefficients of the least absolute shrinkage and selection operation (LASSO) logistic regression. The discrimination, calibration, and clinical use of the nomogram were investigated.
The model that incorporated age, body mass index, preoperative eGFR, and hydroureteronephrosis was developed with an area under the curve of 0.771, which was confirmed to be 0.773 in the external validation set. The calibration curve demonstrated good agreement. Besides, the model was converted into a risk score with a cutoff value of 0.583, and the difference between the low- and high-risk groups both in overall death risk (hazard ratio [HR]: 4.59, p < 0.001) and cancer-specific death risk (HR: 5.19, p < 0.001) was statistically significant. The limitation mainly lies in its retrospective design.
A nomogram incorporating immediately available clinical variables can accurately predict renal insufficiency for cisplatin-based adjuvant chemotherapy after minimally invasive RNU and may serve as a tool facilitating patient selection.
We have developed a model for the prediction of renal function loss after radical nephroureterectomy to facilitate patient selection for perioperative chemotherapy.
术后肾功能损害是根治性肾输尿管切除术(RNU)后进行辅助化疗的主要限制因素。
建立一个预测微创RNU后肾功能下降的模型。
设计、设置和参与者:从一个包括全球17家机构的协作数据库中识别出490例接受微创RNU的非转移性上尿路尿路上皮癌(UTUC)患者(2006年2月至2020年3月)。基于顺铂方案的肾功能不全定义为RNU后3个月时估计肾小球滤过率(eGFR)<50 ml/min/1.73 m²。基线eGFR>50 ml/min/1.73 m²的患者(n = 361)按地理位置分为训练集(n = 226)和独立的外部验证集(n = 135)进行进一步分析。
使用个体预后或诊断多变量预测模型的透明报告(TRIPOD)指南,基于最小绝对收缩和选择算子(LASSO)逻辑回归系数构建预测术后eGFR<50 ml/min/1.73 m²的列线图。研究了列线图的辨别力、校准和临床应用。
纳入年龄、体重指数、术前eGFR和肾盂积水的模型曲线下面积为0.771,在外部验证集中确认为0.773。校准曲线显示出良好的一致性。此外,该模型转换为风险评分,临界值为0.583,低风险组和高风险组在总体死亡风险(风险比[HR]:4.59,p<0.001)和癌症特异性死亡风险(HR:5.19,p<0.001)方面的差异具有统计学意义。局限性主要在于其回顾性设计。
一个纳入即时可用临床变量的列线图可以准确预测微创RNU后基于顺铂辅助化疗的肾功能不全,并可作为促进患者选择的工具。
我们开发了一个根治性肾输尿管切除术后肾功能丧失的预测模型,以促进围手术期化疗患者的选择。